Careers Contact Overview Transactions News Our Team MTS HEALTH PARTNERS » TRANSACTION EXPERIENCE Transaction Type Client Type Sort by Date SHOW: All Transactions The below represents select transactions BehaVR Announced: 10/18/2021 | Value: Up to $163 million MTS served as exclusive financial advisor to BehaVR on its collaboration with Sumitomo Dainippon Pharma One Medical Passport Announced: 10/5/2021 | Value: Undisclosed MTS served as exclusive financial advisor to One Medical Passport on its sale to Mnet Health JCR Pharmaceuticals Co., Ltd. Announced: 9/30/2021 | Value: Undisclosed MTS served as exclusive financial advisor to JCR Pharmaceuticals on its collaboration and license agreement to commercialize JR-141 with Takeda Pharmaceutical Arbor Pharmaceuticals, Inc Announced: 8/24/2021 | Value: Undisclosed MTS served as exclusive financial advisor to Arbor Pharmaceuticals on its sale to Azurity Pharmaceuticals ImmunoTek Announced: 7/30/2021 | Value: Undisclosed MTS served as exclusive financial advisor to ImmunoTek on its development and supply agreement with Grifols MedRhythms Announced: 7/28/2021 | Value: $25 million MTS served as exclusive placement agent to MedRhythms on its $25 million Series B financing Otsuka Pharmaceutical Announced: 7/23/2021 | Value: $20 million MTS served as the exclusive financial advisor to Otsuka America Pharmaceutical on the divestiture of its North American BreathTek business to Meridian Bioscience Seres Therapeutics, Inc. Announced: 7/1/2021 | Value: $525 million MTS served as the exclusive financial advisor to Seres Therapeutics on its co-commercialization license agreement with Nestlé Health Science for SER-109 Catalyst Pharmaceuticals, Inc. Announced: 6/28/2021 | Value: Undisclosed MTS served as the exclusive financial advisor to Catalyst Pharmaceuticals on its outlicensing of Firdapse in Japan to DyDo Pharma onehome Announced: 6/14/2021 | Value: Undisclosed MTS served as lead financial advisor to onehome on its sale to Humana Kinderhook Industries, Inc. Announced: 6/14/2021 | Value: Undisclosed MTS served as exclusive financial advisor to Kinderhook Industries’ portfolio company on acquisition of Medical Card System Strongbridge Biopharma Announced: 5/24/2021 | Value: $267 million MTS served as exclusive financial advisor to Strongbridge Biopharma on its sale to Xeris Pharmaceuticals Synzi Announced: 5/7/2021 | Value: $42.5 million MTS served as exclusive financial advisor to Synzi on its sale to AMN Healthcare Applied Genetic Technologies Corporation (AGTC) Announced: 1/28/2021 | Value: $75 million Joint bookrunner and financial advisor on the confidentially marketed public offering (CMPO) for Applied Genetic Technologies Corporation (NASDAQ: AGTC) Acorda Therapeutics Announced: 1/13/2021 | Value: $80 million MTS served as exclusive financial advisor to Acorda on its sale of a spray drying manufacturing facility Magellan Health, Inc. Announced: 12/22/2020 | Value: Undisclosed MTS served as exclusive financial advisor to Magellan on its acquisition of a majority interest in Bayless Integrated Healthcare Neos Therapeutics, Inc. Announced: 12/10/2020 | Value: Undisclosed MTS served as exclusive financial advisor to Neos Therapeutics on its stock-for-stock merger with Aytu Bioscience Sunesis Pharmaceuticals, Inc. Announced: 11/30/2020 | Value: Undisclosed Financial advisor to Sunesis Pharmaceuticals, Inc. on its all-stock merger with Viracta Therapeutics, Inc. Cystic Fibrosis Foundation Announced: 11/2/2020 | Value: $575 million upfront plus a $75 million potential milestone payment MTS served as exclusive financial advisor to the Cystic Fibrosis Foundation in the structured sale of its residual royalty interests in Vertex’s Cystic Fibrosis Assets Magellan Health, Inc. Announced: 10/29/2020 | Value: Undisclosed MTS served as exclusive financial advisor to Magellan on its strategic minority equity investment in Kaden Health doctor.com Announced: 10/13/2020 | Value: Undisclosed MTS served as exclusive financial advisor to doctor.com on its sale to Press Ganey Associates University of Maryland Medical System Announced: 10/12/2020 | Value: Undisclosed Exclusive financial advisor to the University of Maryland Medical System in connection with the sale of its Medicare and Medicaid plans to CareFirst Blue Cross Blue Shield Galecto Inc. Announced: 9/25/2020 | Value: $64 million Placement agent for Galecto Inc. on its $64mm Crossover financing Strongbridge Biopharma Announced: 9/16/2020 | Value: $25 million MTS served as financial advisor to Strongbridge Biopharma on its public offering MiNA Therapeutics Announced: 9/10/2020 | Value: £23 million Exclusive placement agent for MiNA Therapeutics on its £23 million ($30mm) Series A financing Verastem Oncology Announced: 8/10/2020 | Value: Up to $311 million plus double-digit royalty on US + EU sales and 50% of net royalties on previously out licensed regions MTS served as financial advisor to Verastem Oncology in Sale of COPIKTRA to Secura Bio Lexicon Pharmaceuticals Announced: 7/30/2020 | Value: Up to $224 million MTS served as financial advisor to Lexicon Pharmaceuticals in Sale of XERMELO to TerSera Therapeutics Healthcare Merger Corp Announced: 7/29/2020 | Value: $720 million MTS served as financial advisor to Healthcare Merger Corp on its merger with SOC Telemed Chinook Therapeutics Announced: 6/2/2020 | Value: Undisclosed Exclusive financial advisor to Chinook Therapeutics on its all-stock reverse merger with Aduro Biotech Larimar Therapeutics Announced: 5/29/2020 | Value: $80 million MTS Served as exclusive placement agent to Larimar Therapeutics (NASDAQ:LRMR) on its $80mm PIPE financing Geron Corporation Announced: 5/21/2020 | Value: $150 million Joint bookrunner on the confidentially marketed public offering for Geron Corporation (NASDAQ: GERN) scPharmaceuticals Announced: 5/20/2020 | Value: $50 million MTS served as financial advisor in public offering of common stock Quorum Health Corporation Announced: 4/7/2020 | Value: $1.3 billion MTS served as exclusive financial advisor to Quorum in connection with the prepackaged Chapter 11 recapitalization JCR Pharmaceuticals Co., Ltd Announced: 3/26/2020 | Value: Undisclosed MTS served as exclusive financial advisor to JCR Pharmaceuticals (TSE:4552) on its acquisition of ArmaGen Zyla Life Sciences Announced: 3/16/2020 | Value: Undisclosed MTS served as exclusive financial advisor to Zyla Life Sciences on its stock-for-stock merger with Assertio Therapeutics Pager, Inc. Announced: 3/9/2020 | Value: $33 million Exclusive financial advisor to Pager on its $33mm private placement Lincare Announced: 3/4/2020 | Value: Undisclosed MTS served as exclusive financial advisor to Lincare on its sale of Home Infusion assets to KabaFusion R1 RCM Announced: 1/13/2020 | Value: $190 million Served as financial advisor to R1 RCM (NASDAQ: RCM) on its acquisition of SCI Solutions Universal Care, Inc. (d/b/a/ Brand New Day) Announced: 1/8/2020 | Value: $280 million Exclusive financial advisor to Universal Care, Inc. (d/b/a/ Brand New Day) on its sale to Bright Health Healthgrades Announced: 1/7/2020 | Value: Undisclosed MTS served as exclusive financial advisor to Healthgrades on its acquisition of Evariant Gilead Sciences, Inc. Announced: 12/24/2019 | Value: Undisclosed Exclusive financial advisor to Gilead Sciences on its co-promotion of FILGOTINIB with Eisai in Japan Zafgen, Inc. Announced: 12/18/2019 | Value: Undisclosed Exclusive financial advisor to Zafgen, Inc. on its all-stock merger with Chondrial Therapeutics, Inc. Veloxis Pharmaceuticals A/S Announced: 11/25/2019 | Value: $1.318 billion Exclusive financial advisor to Veloxis on its sale to Asahi Kasei Group Blue Cross and Blue Shield of Arizona, Inc. Announced: 11/7/2019 | Value: Undisclosed Exclusive financial advisor to Blue Cross and Blue Shield of Arizona, Inc. on its pending acquisition of Steward Health Choice Arizona from Steward Health Care System Roivant Sciences Announced: 10/31/2019 | Value: $3.0 billion Exclusive financial advisor to Roivant in its sale of select assets, access to Health technology, and 10% equity to Dainippon Sumitomo Pharma Genesis HealthCare Announced: 10/16/2019 | Value: $89 million for the sale of 8 facilities and undisclosed value of JV in 18 facilities with undisclosed investor MTS served as financial advisor to Genesis Healthcare on its sale of 8 facilities and formation of a joint venture in 18 facilities with an undisclosed investor H. Lundbeck A/S Announced: 9/16/2019 | Value: $2.0 billion MTS served as financial advisor to Lundbeck on its acquisition of Alder BioPharmaceuticals Cavion, Inc. Announced: 8/12/2019 | Value: Up to $312.5 million Exclusive financial advisor to Cavion in connection with its sale to Jazz Pharmaceuticals Neoleukin Therapeutics, Inc. Announced: 8/6/2019 | Value: Undisclosed Exclusive financial advisor to Neoleukin Therapeutics on its reverse merger with Aquinox Pharmaceuticals Vical Incorporated Announced: 6/3/2019 | Value: Undisclosed Exclusive Financial Advisor to Vical Incorporated on its all-stock merger with Brickell Biotech, Inc. Amryt Pharma plc Announced: 5/21/2019 | Value: $518 million in combined enterprise value, plus up to an additional $85mm in CVRs to Amryt shareholders Exclusive financial advisor to Amryt Pharma plc on its all-stock merger with Aegerion Pharmaceuticals, Inc. LifeArc Announced: 5/20/2019 | Value: $1.297 billion MTS served as exclusive financial advisor to LifeArc on the structured sale of a portion of its worldwide royalty interests in Keytruda Realm Therapeutics Announced: 5/16/2019 | Value: Financial advisor to Realm Therapeutics on its reverse merger with ESSA Pharma University of Newcastle upon Tyne Announced: 4/1/2019 | Value: $31 million Exclusive financial advisor to Newcastle University in the structured sale of a portion of its royalty interests in RUBRACA Promise Healthcare Announced: 2/13/2019 | Value: $84 million Exclusive financial advisor to Promise Healthcare Group in its Section 363 sale of Silver Lake Medical Center to L.A. Downtown Medical Center Arsenal Capital Partners Announced: 1/17/2019 | Value: Undisclosed MTS served as exclusive financial advisor to Arsenal Capital Partners on its acquisition of Accumen Inc. Activate Healthcare Announced: 1/16/2019 | Value: Undisclosed MTS served as exclusive financial advisor to Activate Healthcare on its acquisition by Paladina Health. SMV Property Holdings Announced: 1/11/2019 | Value: $835 million MTS Health Partners acted as exclusive financial advisor to SMV Property Holdings in connection with a $835mm refinancing Immunogen, Inc. Announced: 1/8/2019 | Value: $65 million Exclusive financial advisor to ImmunoGen on its sale of residual Kadcyla royalties Shionogi & Co., Ltd. Announced: 12/19/2018 | Value: Upfront of $5 million and equity investment of $35 million, plus milestones up to $120mm and tiered royalty on sales if successfully commercialized Exclusive financial advisor to Shionogi on its strategic collaboration with Tetra Discovery Partners to license Tetra’s BPN14770 in Japan, Taiwan and Korea. Strongbridge Biopharma Announced: 10/31/2018 | Value: ~$182 million cash and PIPE investment plus additional undisclosed amount for inventory and sales force for three years Exclusive financial advisor to Strongbridge Biopharma on its sale of US and Canadian rights for Macrilen to Novo Nordisk Adynxx Announced: 10/12/2018 | Value: Undisclosed Exclusive financial advisor to Adynxx on its all-stock merger agreement with Alliqua BioMedical Otsuka Pharmaceutical Announced: 10/11/2018 | Value: $80 million Exclusive Financial Advisor to Otsuka on its expanded collaboration agreement with Proteus to Advance Digital Medicines For Mental Health Poxel Announced: 8/30/2018 | Value: Upfront ~$18 million, plus additional undisclosed development and commercial milestones Exclusive financial advisor to Poxel on its acquisition of DRX-065 and other programs from DeuteRx Ligand Pharmaceuticals Announced: 8/9/2018 | Value: £32.8 million Financial advisor to Ligand Pharmaceuticals in its acquisition of Vernalis Psyadon Pharmaceuticals Announced: 8/8/2018 | Value: Undisclosed Exclusive financial advisor to Psyadon Pharmaceuticals in connection with its sale to Paragon Biosciences ReViral Announced: 8/1/2018 | Value: $55 million Exclusive placement agent for ReViral Ltd on its $55mm Series B financing Protalix BioTherapeutics Announced: 7/24/2018 | Value: Up to $805 million Exclusive financial advisor to Protalix on its sale of the U.S. commercialization and development rights for PRX-102 to Chiesi Farmaceutici Apollo Global Management / RCCH HealthCare Partners Announced: 7/23/2018 | Value: $5.6 billion MTS served as financial advisor to Apollo/RCCH on its $5.6 Billion Cash Merger with LifePoint Health (NASDAQ: LPNT) Jazz Pharmaceuticals Announced: 6/29/2018 | Value: $80 million Exclusive Financial Advisor to Jazz Pharmaceuticals in its sale of Prialt to TerSera Therapeutics. Dana-Farber Cancer Institute Announced: 6/29/2018 | Value: Undisclosed MTS served as exclusive financial advisor to Dana-Farber on the sale of royalty interests Keryx Biopharmaceuticals Announced: 6/28/2018 | Value: $1.3 billion Financial advisor to Keryx Biopharmaceuticals in its all-stock merger with Akebia Therapeutics University of Massachusetts Medical School Announced: 6/22/2018 | Value: Undisclosed Exclusive financial advisor to the University of Massachusetts Medical School in the structured sale of a portion of its US royalty interests in SPINRAZA Boston Children’s Hospital Announced: 6/19/2018 | Value: $51.5 million Exclusive financial advisor to Boston Children’s Hospital in the structured sale of royalty interests in VONVENDI Shionogi & Co., Ltd. Announced: 6/13/2018 | Value: Upfront $90 million, plus additional development and commercial milestones of up to $485 million Exclusive financial advisor to Shionogi on its strategic collaboration with Sage Therapeutics to develop and commercialize SAGE-217 in Japan, Taiwan and South Korea Cold Spring Harbor Laboratory Announced: 6/12/2018 | Value: Undisclosed Exclusive financial advisor to CSHL in the structured sale of a portion of its worldwide royalty interests in SPINRAZA Cyteir Therapeutics Announced: 4/30/2018 | Value: $35 million Sole placement agent Arbutus Biopharma Announced: 4/11/2018 | Value: Undisclosed MTS advised the Special Committee to the Board of Directors of Arbutus on the launch of Genevant Sciences, a jointly-owned company with Roivant Sciences pSivida Announced: 3/28/2018 | Value: Up to $125 million Exclusive financial advisor to pSivida in connection with its acquisition of Icon Bioscience to form EyePoint Pharmaceuticals Ameritox Announced: 3/5/2018 | Value: Undisclosed Exclusive financial advisor to Ameritox in connection with its sale to Aegis Sciences Corporation, a portfolio company of Abry Partners Addex Therapeutics Announced: 3/5/2018 | Value: $42.6 million Sole US placement agent for Addex Therapeutics (SWX: ADXN) in connection with a $42.6 million PIPE financing Churchill Pharmaceuticals Announced: 1/25/2018 | Value: Undisclosed Partner Exclusive financial advisor to Churchill Pharmaceuticals on its outlicensing of YONSA to an Undisclosed Partner Strongbridge Biopharma Announced: 1/17/2018 | Value: Up to $203 million Acquisition of US and Canadian rights to MACRILEN from Aeterna Zentaris Novozymes Announced: 12/28/2017 | Value: Undisclosed Exclusive financial advisor to Novozymes on the divestiture of Albumedix ImmusanT Announced: 11/14/2017 | Value: $40 million Sole placement agent in Series C private financing Ocera Therapeutics Announced: 11/2/2017 | Value: Up to $117 million Clinical-stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate) in both intravenous (IV) and oral formulations Envisia Therapeutics Announced: 10/5/2017 | Value: $25 million plus additional undisclosed product approval milestones Exclusive financial advisor to Envisia Therapeutics on its asset sale to Aerie Pharmaceuticals Arbutus Biopharma Announced: 10/2/2017 | Value: $116.4 million Financial Advisor to Special Committee of the Board of Directors on Private Placement Dimension Therapeutics Announced: 10/2/2017 | Value: $171 million Exclusive financial advisor to Dimension Therapeutics in connection with its sale to Ultragenyx Pharmaceutical Realm Therapeutics Announced: 9/21/2017 | Value: $26 million Realm Therapeutics (AIM:RLM) announced an upsized $26 million private placement Walter and Eliza Hall Institute Announced: 7/27/2017 | Value: $325 million Exclusive financial advisor to WEHI in the structured sale of a portion of its worldwide royalty interests in venetoclax Physicians Dialysis and GMF Capital Announced: 5/1/2017 | Value: Undisclosed Exclusive financial and debt advisor to Physicians Dialysis and GMF Capital in connection with acquisition of assets from DaVita Zymeworks Announced: 4/27/2017 | Value: $59 million Financial advisor to Zymeworks in connection with its IPO Verona Pharma plc Announced: 4/26/2017 | Value: $80 million Financial advisor to Verona Pharma in connection with its U.S. IPO Caladrius Biosciences Announced: 3/16/2017 | Value: $75 million upfront, plus $5 million additional potential sales milestone payment Exclusive financial advisor to Caladrius Biosciences on the sale of its remaining 80.1% equity stake in its PCT, LLC subsidiary Otsuka Pharmaceutical Announced: 3/2/2017 | Value: $100 million upfront, plus up to $150mm in development & regulatory milestones, plus additional potential sales milestone payments Exclusive financial advisor to Otsuka Pharmaceutical Co., Ltd. on its acquisition of Neurovance, Inc. Arizona Center for Cancer Care Announced: 1/30/2017 | Value: Undisclosed Exclusive financial advisor to AZCCC in connection with its Joint Venture with HonorHealth CoLucid Pharmaceuticals Announced: 1/18/2017 | Value: $960 million Exclusive sell-side advisor to CoLucid Pharmaceuticals on its sale to Eli Lilly and Company Ipsen Announced: 1/8/2017 | Value: $575 million plus up to $450 million in contingent payments Exclusive financial advisor to Ipsen on its acquisition of Onivyde from Merrimack Pharmaceuticals OncoGenex Pharmaceuticals Announced: 1/5/2017 | Value: Undisclosed Exclusive financial advisor to OncoGenex Pharmaceuticals on its all-stock merger agreement with Achieve Life Science Shire plc (NASDAQ:SHPG) Announced: 1/4/2017 | Value: Undisclosed Exclusive financial advisor to Shire on the spin-out of its MRT platform to RaNA Therapeutics Universal American Announced: 11/17/2016 | Value: $800 million MTS advised Universal American on its sale to WellCare Health Plans Ocular Technologies (an Auven Therapeutics portfolio company) Announced: 10/26/2016 | Value: $40 million plus contingent payments Exclusive financial advisor to Auven Therapeutics in the sale of Seciera, a Phase 3 clinical asset for the treatment of dry eye disease Horizon Pharma Plc Announced: 9/12/2016 | Value: $800 million Lead financial advisor to Horizon Pharma Plc on its acquisition of Raptor Pharmaceutical PathGroup Announced: 8/1/2016 | Value: Undisclosed Exclusive financial advisor to PathGroup in connection with its sale to Pritzker Group Private Capital Dana-Farber Cancer Institute Announced: 7/29/2016 | Value: $168 million Long-term exclusive financial advisor to DFCI in the structured sale of a portion of its royalty interests in certain PD-L1 products and product candidates Medical Research Council Technology Announced: 7/8/2016 | Value: $150 million Exclusive financial advisor to MRCT in the structured sale of a portion of its worldwide royalty interests in KEYTRUDA Bloom Health Announced: 07/06/2016 | Value: Undisclosed Sole advisor to Bloom Health on its sale to Empyrean Benefit Solutions Verona Pharma Announced: 06/17/2016 | Value: $63.3 million Sole US placement agent for Verona Pharma in connection with raising $63.3 million in a PIPE financing Celator Pharmaceuticals Announced: 05/31/2016 | Value: $1.5 billion Exclusive financial advisor to Celator in connection with its sale to Jazz Pharmaceuticals Synta Pharmaceuticals Announced: 04/14/2016 | Value: Undisclosed Financial Advisor to Synta Pharmaceuticals on its all-stock merger agreement with Madrigal Pharmaceuticals Madrigal Pharmaceuticals Announced: 04/14/2016 | Value: Undisclosed Strategic Advisor to Madrigal Pharmaceuticals on its all-stock merger agreement with Synta Pharmaceuticals Starmount Announced: 04/04/2016 | Value: $127 million Exclusive financial advisor to Starmount in connection with its sale to Unum Group (NYSE: UNM) Celator Pharmaceuticals Announced: 03/23/2016 | Value: $44 million Financial advisor to Celator Pharmaceuticals (NASDAQ:CPXX) on its $43.7 Million Public Offering Caladrius Biosciences Announced: 03/14/2016 | Value: $25 million Exclusive financial advisor to Caladrius Biosciences on its Strategic Global Collaboration and Asia License Agreement with Hitachi Chemical (19.9% Equity Stake for $19.4 Million and $5.6 Million Upfront) Signature Hospice and Home Health Announced: 03/09/2016 | Value: $84 million Exclusive financial advisor to Genesis Healthcare (NYSE: GEN) on the sale of its Signature Hospice and Home Health operations to Hospice Compassus Laurel Health Care Company Announced: 02/02/2016 | Value: Undisclosed Sale of real estate assets to Omega Healthcare Investors as well as the sale of operations to Ciena Healthcare Tarveda Therapeutics (formerly Blend Therapeutics) Announced: 01/27/2016 | Value: $38 million Sole placement agent for Tarveda Therapeutics on its $38 Million Private Placement Acorda Therapeutics Announced: 01/19/2016 | Value: $363 million Financial advisor to Acorda Therapeutics on the acquisition of Biotie Therapies Aprecia Pharmaceuticals Announced: 01/14/2016 | Value: $50 million Sole placement agent for Aprecia Pharmaceuticals on its $50 Million Private Placement Zymeworks Announced: 01/08/2016 | Value: $62 million Lead placement agent for Zymeworks in connection with raising $61.5 million of Series A financing Diffusion Pharmaceuticals LLC Announced: 12/15/2015 | Value: Undisclosed Exclusive financial advisor to Diffusion Pharmaceuticals on its merger with RestorGenex Corporation Velicept Therapeutics Announced: 11/24/2015 | Value: $20 million Sole placement agent for Velicept Therapeutics on its $20 million Private Placement Examination Management Services Inc. Announced: 11/03/2015 | Value: Undisclosed Exclusive financial advisor to EMSI in connection with its sale to Beecken Petty O’Keefe StrataDx Announced: 10/01/2015 | Value: Undisclosed Exclusive financial advisor to StrataDx in connection with its sale to Dermatopathology Experts Health Diagnostic Laboratory Announced: 09/11/2015 | Value: $37.1 million Financial advisor to HDL in its Section 363 sale to True Health Diagnostics Tripex Pharmaceuticals Announced: 08/20/2015 | Value: $418.4 million Exclusive advisor for Tripex in connection with its sale of Quinsair to Raptor Pharmaceuticals Celsus Therapeutics Announced: 08/18/2015 | Value: $75 million Placement agent for Celsus in connection with raising $75 million in a PIPE financing TeamHealth Announced: 08/04/2015 | Value: $1.6 billion Financial advisor to TeamHealth on its acquisition of IPC Healthcare Celsus Therapeutics Announced: 07/13/2015 | Value: Undisclosed Financial advisor to Celsus Therapeutics on its merger with Volution Immuno Pharmaceuticals ARCA biopharma Announced: 06/11/2015 | Value: $37 million Sole placement agent for ARCA biopharma in connection with raising $37 million in a PIPE financing University of Maryland Medical System Announced: 05/14/2015 | Value: Not Disclosed Exclusive advisor for the University of Maryland Medical System in connection with its acquisition of Riverside Health Baxter International Inc. Announced: 05/12/2015 | Value: $900 million Financial advisor to Baxter International Inc. on its acquisition of Oncaspar Portfolio from Sigma-Tau Finanziaria S.p.A ImmunoGen, Inc. Announced: 03/30/2015 | Value: $200 million Exclusive financial advisor to ImmunoGen, Inc. in the structured sale of a portion of its worldwide royalty interests in Kadcyla Champions Oncology Announced: 03/12/2015 | Value: $14 million Sole placement agent for Champions Oncology in connection with raising $14 million in a PIPE financing TRACON Pharmaceuticals, Inc. Announced: 01/29/2015 | Value: $41 million Financial advisor to TRACON Pharmaceuticals, Inc. in connection with its Initial Public Offering Regado Biosciences Announced: 01/14/2015 | Value: Not Disclosed Financial advisor to Regado Biosciences on its merger with Tobira Therapeutics Otsuka Pharmaceutical Announced: 12/02/2014 | Value: $3.54 billion Financial advisor to Otsuka Pharmaceutical Co., Ltd. on its acquisition of Avanir Pharmaceuticals, Inc. Community Health Systems Announced: 11/07/2014 | Value: Not Disclosed Exclusive financial advisor to Community Health Systems on its divestiture of Riverview Regional Medical Center to Prime Healthcare Services GE Capital, Healthcare Financial Services Announced: 11/05/2014 | Value: $305 million Exclusive financial advisor to GE Capital, Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Aviv REIT Paul Capital Announced: 10/17/2014 | Value: Not Disclosed Exclusive financial advisor to Paul Capital on the secondary sale of royalty streams generated by seven pharmaceuticals Community Health Systems Announced: 10/13/2014 | Value: Not Disclosed Exclusive financial advisor to Community Health Systems on its divestiture of Carolina Pines Regional Medical Center to Capella Healthcare WellSpring Pharmaceutical Announced: 10/03/2014 | Value: Not Disclosed Exclusive financial advisor to WellSpring Pharmaceutical Corporation on the sale of its Prescription Pharmaceutical Business Acorda Therapeutics Announced: 09/24/2014 | Value: $525 million Financial advisor to Acorda Therapeutics on the acquisition of Civitas Therapeutics TRACON Pharmaceuticals Announced: 09/22/2014 | Value: $27 million Lead placement agent for Tracon in connection with raising $27.0 million of Series B financing Aerie Pharmaceuticals, Inc. Announced: 09/09/2014 | Value: $125 million Exclusive financial advisor to Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) to enter into a $125m secured convertible debt facility agreement with Deerfield Capital Management for continued development of product pipeline (Rhopressa™ and Roclatan™), general corporate purposes, and strategic growth opportunities Skilled Healthcare Group Announced: 08/18/2014 | Value: NA Exclusive financial advisor to Skilled Healthcare Group Inc. (NYSE:SKH) on its merger with Genesis HealthCare AesRx Announced: 07/09/2014 | Value: Not Disclosed Exclusive financial advisor to AesRx, LLC on its sale to Baxter International Inc. Nicox Announced: 07/02/2014 | Value: Up to $120 million Exclusive financial advisor to Nicox, SA on its acquisition of Aciex Therapeutics, Inc. Vistria Announced: 06/24/2014 | Value: Not Disclosed Financial advisor to Vistria on its acquisition of Angel MedFlight Cymetrix Announced: 05/14/2014 | Value: Up to $100 million Financial advisor to Cymetrix on its sale to Navigant Alder Biopharmaceuticals Inc Announced: 05/08/2014 | Value: $80 million Financial advisor to Alder Biopharmaceuticals Inc in connection with its Initial Public Offering Corrona Announced: 04/17/2014 | Value: Not Disclosed MTS acted as financial advisor on the growth recapitalization of Corrona Kaléo Announced: 04/07/2014 | Value: $150 million Exclusive financial advisor to kaléo to enter into a $150 million debt facility with PDL BioPharma (NASDAQ: PDLI) to enable kaléo to support commercialization of EVZIO™ (naloxone hydrochloride injection) and development of key pipeline products Promise Healthcare Announced: 04/02/2014 | Value: Not Disclosed Financial advisor to Promise Healthcare, Inc. on its acquisition of six healthcare facilities including four long-term acute care hospitals and two skilled nursing facilities Oxygen Biotherapeutics Announced: 03/18/2014 | Value: $59.8 million MTS served as underwriter for the transaction and led efforts with institutional investors participating in the offering Promise Healthcare Announced: 03/17/2014 | Value: Not Disclosed Financial advisor to Promise Healthcare, Inc. on its restructuring NuPathe Inc. Announced: 01/21/2014 | Value: $268 million Financial advisor to NuPathe Inc. on its sale to Teva Pharmaceutical Industries. Iroko Pharmaceuticals Announced: 11/21/2013 | Value: $75 million Exclusive financial advisor to Iroko to enter into a $75m debt facility agreement to support general business operations and the launch of Zorvolex (diclofenac) Almost Family, Inc. Announced: 11/5/2013 | Value: $75.5 million Financial advisor to Almost Family, Inc. on its acquisition of SunCrest Healthcare Miraca Life Sciences Announced: 10/23/2013 | Value: Not Disclosed Financial advisor to Miraca Life Sciences on its acquisition of PLUS Diagnostics La Jolla Pharmaceutical Announced: 09/25/2013 | Value: $10 million Sole placement agent for La Jolla Pharmaceutical Company in connection with raising $10.0 million through common and preferred shares Celsus Therapeutics Announced: 09/19/2013 | Value: $12.5 million Placement agent for Celsus Therapeutics in connection with raising $12.5 million through common shares QuantiaMD Announced: 9/3/2013 | Value: $10 million Sole placement agent for Quantia Communications, Inc. on its $10 million Private Placement Acorda Therapeutics Announced: 7/9/2013 | Value: Not Disclosed Financial advisor to Acorda Therapeutics on the acquisition of Qutenza™ and NP-1998 from NeurogesX University of Pennsylvania Announced: 6/25/2013 | Value: $55 million Exclusive financial advisor to University of Pennsylvania in the structured sale of a portion of its worldwide royalty interests in Juxtapid Laboratory Partners Announced: 6/3/2013 | Value: Not Disclosed Financial advisor to Laboratory Partners on the sale of its physician outreach business AmeriHealth Caritas Announced: 5/1/2013 | Value: Not Disclosed Financial advisor to AmeriHealth Caritas on its acquisition of DC Chartered Health Plan assets RXi Pharmaceuticals Corporation Announced: 3/1/2013 | Value: $16.4 million Sole placement agent for RXI Pharmaceuticals Corp. in connection with raising $16.4 million through the sale of common shares Progenics Pharmaceuticals Announced: 1/22/2013 | Value: Up to $105 million Financial advisor to Progenics Pharmaceuticals, Inc on its acquisition of Molecular Insight Pharmaceuticals TractManager Inc. Announced: 1/7/2013 | Value: Not Disclosed Exclusive financial advisor to TractManager, Inc. in connection with the majority recapitization investment by Arsenal Capital Partners Florida Clinical Laboratory Announced: 12/31/2012 | Value: Not Disclosed Exclusive financial advisor to Florida Clinical Laboratory on its sale to Bio-Reference Laboratories, Inc. BioScrip Announced: 12/13/2012 | Value: $70 million Financial advisor to BioScrip Inc. on its acquisition of HomeChoice Partners, Inc. from DaVita HealthCare Partners GE Capital, Healthcare Financial Services Announced: 12/1/2012 | Value: Not Disclosed Exclusive financial advisor to GE Healthcare Financial Services in its sale of a Long Term Care Real Estate Portfolio to Formation Capital MethylGene Announced: 11/21/2012 | Value: $26 million Acted as a placement agent for MethylGene in connection with raising $26MM in a PIPE financing NuPathe Announced: 10/23/2012 | Value: $28 million Co-placement agent for NuPathe, Inc. in connection with raising $28 million in a PIPE financing Fibrocell Science Announced: 10/8/2012 | Value: $45 million Lead placement agent for Fibrocell Science, Inc. in connection with raising $45 million in a PIPE financing. Strategic Advisor to Fibrocell Science, Inc on its strategic collaboration with Intrexon Jazz Pharmaceuticals Announced: 9/6/2012 | Value: $95 Million Exclusive financial advisor to Jazz Pharmaceuticals on the sale of its Women’s Health Business to Meda AB Idenix Pharmaceuticals Announced: 8/2/2012 | Value: $176 million Financial advisor to Idenix Pharmaceuticals, Inc. on its $176 million follow-on public offering of common stock BioScrip Announced: 7/31/2012 | Value: $41 million Financial advisor to BioScrip Inc. on its acquisition of InfuScience from Cressey & Company Not Disclosed Announced: 6/30/2012 | Value: Not Disclosed Financial advisor to Undisclosed Public Buyer on its acquisition of Healthy Circles Sun Healthcare Announced: 6/20/2012 | Value: $275 million Exclusive financial advisor to Sun Healthcare on its sale to Genesis Healthcare Lumeris Corporation Announced: 2/14/2012 | Value: Not Disclosed Financial advisor to Lumeris Corp. on its acqusition of NaviNet in partnership with Highmark, Horizon Blue Cross Blue Shield of New Jersey and Independence Blue Cross BioScrip Announced: 2/2/2012 | Value: $285 million Financial advisor to BioScrip Inc. on its sale of its community specialty pharmacies and centralized specialty and mail service pharmacy businesses to Walgreens Idenix Pharmaceuticals Announced: 11/16/2011 | Value: $61.1 million Financial advisor to Idenix Pharmaceuticals, Inc. on its $61 million follow-on public offering of common stock A.P. Pharma Announced: 6/29/2011 | Value: $24 million Sole placement agent for AP Pharma in connection with raising $24 million in a PIPE financing Highmark Announced: 6/28/2011 | Value: $1.3 billion Financial advisor to Highmark Inc. in connection with its acquisition of West Penn Allegheny Health System Trimeris Announced: 6/13/2011 | Value: $285 million Exclusive financial advisor to Trimeris Inc. on its reverse merger with Synageva BioPharma Corp Advanced Vision Research Announced: 5/3/2011 | Value: $26 million Exclusive financial advisor to Advanced Vision Research on its sale to Akorn, Inc. MethylGene Announced: 3/24/2011 | Value: $35 million Sole placement agent for MethylGene in connection with raising $35 million in a PIPE financing Intercell AG Announced: 2/23/2011 | Value: $45.5 million Financial advisor to Intercell AG related to the issuance of senior unsecured convertible notes Sol Amor Hospice Announced: 1/3/2011 | Value: Not Disclosed Exclusive financial advisor to Sun Healthcare and its subsidiary SolAmor Hospice on its acquisition of Countryside Hospice Acadia Pharmaceuticals Announced: 1/1/2011 | Value: $15 million Co-placement agent for Acadia Pharmaceuticals Inc. in connection with raising $15 million in a PIPE financing Aastrom Biosciences Announced: 12/10/2010 | Value: $22.5 million Financial advisor to Aastrom Biosciences for its $22.5 million follow-on offering Neurologix Announced: 12/6/2010 | Value: $7 million Lead placement agent for Neurologix, Inc. in connection with raising $7 million in convertible debt Reata Pharmaceuticals Announced: 9/23/2010 | Value: $450 million Strategic advisor to Reata Pharmaceuticals in its landmark ex-US partnership with Abbott Labs Sun Healthcare Announced: 8/13/2010 | Value: $238 million Financial advisor to Sun Healthcare on its equity offering in connection with its restructuring and spinof of its real estate assets Solstice Neurosciences Announced: 8/13/2010 | Value: Not Disclosed Exclusive financial advisor to Solstice Neurosciences, LLC on its sale to US WorldMeds Trubion Pharmaceuticals Announced: 8/12/2010 | Value: Up to $140 million Financial advisor to Trubion Pharmaceuticals on its sale to Emergent Biosolutions NuPathe Announced: 8/6/2010 | Value: $50 million Financial advisor to NuPathe, Inc in connection with its Initial Public Offering Westcliff Medical Laboratories Announced: 7/18/2010 | Value: $74 million Exclusive financial advisor to Westcliff Medical Laboratories on its restructuring and sale to Laboratory Corporation of America Accolade Announced: 7/1/2010 | Value: $17 million Sole placement agent for Accolade LLC on its $17 million Private Placement Sun Healthcare Announced: 5/24/2010 | Value: $1.6 billion Financial advisor to Sun Healthcare on its spin of real estate assets into separately traded Sabra Health Care REIT (SBRA) Inhibitex Announced: 10/26/2009 | Value: $23 million Exclusive placement agent for Inhibitex, Inc. in connection with raising $23 million in a PIPE financing Threshold Pharmaceuticals Announced: 10/6/2009 | Value: $35 million Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $35 million in a PIPE financing Neurogen Corporation Announced: 8/24/2009 | Value: $11 - 27 million Exclusive financial advisor to Neurogen Corporation on its Sale to Ligand Pharmaceuticals Incorporated Reata Pharmaceuticals Announced: 3/27/2009 | Value: $32 million Sole placement agent for Reata Pharmaceuticals, Inc on its $32 million Private Placement Undisclosed Not-for-Profit Managed Care Organization Announced: 2009 | Value: $37 million Divestiture of dental insurance business of a not-for-profit insurer GTC Biotherapeutics Announced: 11/3/2008 | Value: $15 million Financial advisor to GTC Biotherapeutics, Inc on its $15 million Convertible Debt financing Oscient Pharmaceuticals Announced: 10/21/2008 | Value: $213 million Dealer manager in connection with debt restructuring and recapitalization Link Medicine Announced: 9/30/2008 | Value: $40 million Sole placement agent for Link Medicine Corporation on its $40 million Private Placement Threshold Pharmaceuticals Announced: 7/10/2008 | Value: $18 million Co-placement agent for Threshold Pharmaceuticals Inc. in connection with raising $18 million in a PIPE financing My Innerview Announced: 2008 | Value: Not Disclosed Exclusive financial advisor in connection with its sale to National Research Corporation (NRCI) Coram Announced: 10/12/2007 | Value: $350 million Exclusive financial advisor in connection with its sale to Apria (AHG) Universal American (UAM) Announced: 2007 | Value: $630 million Financial advisor to priviate equity consortium in connection with its investment to fund the acquisition of MemberHealth Undisclosed Not-for-Profit Managed Care Organization Announced: 2007 | Value: $125 million Acquisition of CompWest Coram Announced: 2007 | Value: Not Disclosed Sale of Canadian infusion portfolio Sun Healthcare Group Announced: 12/1/2006 | Value: $19 million Exclusive financial advisor to Sun Healthcare on its sale of SunPlus Home Health Services to AccentCare Home Health Sun Healthcare Group Announced: 10/19/2006 | Value: $625 million Exclusive financial advisor to Sun Healthcare on its acquisition of Harborside Healthcare Undisclosed Not-for-Profit Managed Care Organization Announced: 2006 | Value: $240 million Acquisition of M-Care Coram Announced: 2006 | Value: Not Disclosed Sale of home infusion portfolio Pacificare (PHSY) Announced: 2005 | Value: $9 billion Sale to UnitedHealthcare (UHG) Undisclosed Not-for-Profit Managed Care Organization Announced: 2005 | Value: Not Disclosed Sale of PPO Business Sun Healthcare Group Announced: 5/19/2005 | Value: $246 million Financial advisor to Sun Healthcare on its acquisition of Peak Medical Pacificare (PHSY) Announced: 2005 | Value: Not Disclosed Acquisition of Pacific Life’s group health insurance business PresGar Companies Announced: 2004 | Value: $135 million Restructuring PresGar Companies Announced: 2004 | Value: Not Disclosed Sale of imaging center portfolio to undislosed buyer Pacificare (PHSY) Announced: 2004 | Value: $532 million Acquisition of American Medical Security Group (AMZ) Sloans Lake Announced: 2004 | Value: $45 million Sale to undiclosed financial buyer Sun Healthcare Group Announced: 2/1/2004 | Value: $1.4 billion Exclusive financial advisor to Sun Healthcare Group on its restructuring Undisclosed Not-for-Profit Managed Care Organization Announced: 2004 | Value: $200 million Structured Financing Undisclosed Not-for-Profit Managed Care Organization Announced: 2003 | Value: $150 million Divestiture Sun Healthcare Group Announced: 9/1/2003 | Value: $75 million Financial advisor to Sun Healthcare on its Senior Debt Financing Sun Healthcare Group Announced: 6/17/2003 | Value: $90 million Exclusive financial advisor to Sun Healthcare on its sale of SunScript Pharmacy Services to Omnicare Pacificare (PHSY) Announced: 2002 | Value: $200 million Advisor to PacifiCare in connection with its High-Yield Financing The Mentor Network Announced: 2001 | Value: $126 million Sale to Madison Dearborn Capital Partners Magellan Health Services (MGLN) Announced: 2001 | Value: $250 million Debt Financing Schein Pharmaceuticals (SHP) Announced: 2000 | Value: $1.4 billion Sale to Watson Pharmaceuticals (WPI) Corporate Office 623 Fifth Avenue 14th Floor New York, NY 10022 P: (212) 887-2100 E: info@mtspartners.com About MTS Overview Our Team Transactions News Disclosures Business Continuity Disclosure Statement Privacy Policies Broker Check Membership FINRA SIPC Securities offered through MTS Securities, LLC. | MTS Securities, LLC is an affiliate of MTS Health Partners, L.P. | © 2021 MTS Health Partners, L.P. All rights reserved.